Diferencias clínicas entre la amiloidosis cardiaca por transtirretina y la cardiopatía hipertensiva / Clinical differences between transthyretin cardiac amyloidosis and hypertensive heart disease

Introducción: Un porcentaje importante de pacientes finalmente diagnosticados de amiloidosis cardIaca por transtirretina (ATTR) fueron previamente diagnosticados de cardiopatía hipertensiva (CHTA), ya que ambas enfermedades suelen cursar con insuficiencia cardíaca (IC) con fracción de eyección preservada (ICFEp) e hipertrofia ventricular. Nuestros objetivos fueron evaluar las diferencias clínicas, electrocardiográficas y ecocardiográficas, y analizar si existe un pronóstico diferencial entre ambas entidades nosológicas. Material y métodos: Se incluyeron retrospectivamente todos los pacientes con CHTA a los que se solicitó una gammagrafía cardíaca con 99mTc-Difosfonatos (GDPD) y estudio de cadenas ligeras en sangre y orina para despistaje de ATTR en nuestro centro, en el periodo 2016-2021. Para el análisis, se excluyeron aquellos diagnosticados de otros tipos de amiloidosis. Resultados: Se analizaron un total de 72 pacientes: 33 fueron diagnosticados de ATTR y 39 de CHTA, finalmente. Los pacientes con ATTR presentaron mayores niveles de troponina I ultrasensible (TnI-US) y propéptido natriurético cerebral N-terminal (NT-ProBNP); en electrocardiograma (ECG) presentaron más frecuentemente patrón de seudoinfarto y alteraciones de la conducción; en ecocardiograma transtorácico (ETT) presentaron mayor grado de hipertrofia ventricular, disfunción ventricular izquierda y parámetros de peor función diastólica, con presiones de llenado más elevadas. En el seguimiento a 4 años, el grupo de ATTR mostró mayor necesidad de marcapasos (MCP), sin evidenciarse evidencias en cuanto a mortalidad, desarrollo de fibrilación auricular o más ingresos por IC. Conclusiones: En nuestra serie, los pacientes con ATTR presentaron diferencias clínicas, electrocardiográficas y ecocardiográficas respecto a aquellos con CHTA, con mayor riesgo necesidad de MCP en el seguimiento.(AU)

Introduction: A significant percentage of patients eventually diagnosed with cardiac transthyretin amyloidosis (TTRA) was previously diagnosed with hypertensive heart disease (HHD), since both conditions usually present with heart failure (HF) with preserved ejection fraction (HFpEF) and ventricular hypertrophy. Our objectives were to evaluate the clinical, electrocardiographic and echocardiographic differences, and to analyse whether there exists a differential prognosis between these two nosological entities. Materials and methods: We retrospectively included all patients with HHD for whom a cardiac scintigraphy with 99mTc-diphosphonate (GDPD) and a free light chains test in blood and urine were ordered for ATTR screening in our centre, in the period between 2016 and 2021. Those diagnosed with other types of amyloidosis were excluded from the analysis. Results: A total of 72 patients were analyzed: 33 were finally diagnosed with TTRA and 39 with CHTA. Patients with TTRA had higher levels of ultrasensitive troponin I (TnI-US) and N-terminal brain natriuretic propeptide (NT-ProBNP); in electrocardiography (ECG) they presented a pseudo-infarction pattern more frequently as well as conduction disturbances; in echocardiography (TTE) they presented a higher degree of ventricular hypertrophy, left ventricular dysfunction and worse diastolic function parameters, with elevated filling pressures. In the 4-year follow-up, the ATTR group showed greater need for pacemaker (PCM), with no evidence regarding mortality, development of atrial fibrillation (AF), or more admissions for heart failure (HF). Conclusions: In our series, patients with TTRA showed clinical, electrocardiographic and echocardiographic differences compared to patients with HHD, with increased risk of need for PCM.(AU)

[Clinical differences between transthyretin cardiac amyloidosis and hypertensive heart disease]. / Diferencias clínicas entre la amiloidosis cardiaca por transtirretina y la cardiopatía hipertensiva.

INTRODUCTION: A significant percentage of patients eventually diagnosed with cardiac transthyretin amyloidosis (TTRA) was previously diagnosed with hypertensive heart disease (HHD), since both conditions usually present with heart failure (HF) with preserved ejection fraction (HFpEF) and ventricular hypertrophy. Our objectives were to evaluate the clinical, electrocardiographic and echocardiographic differences, and to analyse whether there exists a differential prognosis between these two nosological entities. MATERIALS AND METHODS: We retrospectively included all patients with HHD for whom a cardiac scintigraphy with 99mTc-diphosphonate (GDPD) and a free light chains test in blood and urine were ordered for ATTR screening in our centre, in the period between 2016 and 2021. Those diagnosed with other types of amyloidosis were excluded from the analysis. RESULTS: A total of 72 patients were analyzed: 33 were finally diagnosed with TTRA and 39 with CHTA. Patients with TTRA had higher levels of ultrasensitive troponin I (TnI-US) and N-terminal brain natriuretic propeptide (NT-ProBNP); in electrocardiography (ECG) they presented a pseudo-infarction pattern more frequently as well as conduction disturbances; in echocardiography (TTE) they presented a higher degree of ventricular hypertrophy, left ventricular dysfunction and worse diastolic function parameters, with elevated filling pressures. In the 4-year follow-up, the ATTR group showed greater need for pacemaker (PCM), with no evidence regarding mortality, development of atrial fibrillation (AF), or more admissions for heart failure (HF). CONCLUSIONS: In our series, patients with TTRA showed clinical, electrocardiographic and echocardiographic differences compared to patients with HHD, with increased risk of need for PCM.

The Worsening of Heart Failure with Reduced Ejection Fraction: The Impact of the Number of Hospital Admissions in a Cohort of Patients.

BACKGROUND: Worsening heart failure (WFH) includes heart failure (HF) hospitalisation, representing a strong predictor of mortality in patients with heart failure with reduced ejection fraction (HFrEF). However, there is little evidence analysing the impact of the number of previous HF admissions. Our main objective was to analyse the clinical profile according to the number of previous admissions for HF and its prognostic impact in the medium and long term. METHODS: A retrospective study of a cohort of patients with HFrEF, classified according to previous admissions: cohort-1 (0-1 previous admission) and cohort-2 (≥2 previous admissions). Clinical, echocardiographic and therapeutic variables were analysed, and the medium- and long-term impacts in terms of hospital readmissions and cardiovascular mortality were assessed. A total of 406 patients were analysed. RESULTS: The mean age was 67.3 ± 12.6 years, with male predominance (73.9%). Some 88.9% (361 patients) were included in cohort-1, and 45 patients (11.1%) were included in cohort-2. Cohort-2 had a higher proportion of atrial fibrillation (49.9% vs. 73.3%; p = 0.003), chronic kidney disease (36.3% vs. 82.2%; p < 0.001), and anaemia (28.8% vs. 53.3%; p = 0.001). Despite having similar baseline ventricular structural parameters, cohort-1 showed better reverse remodelling. With a median follow-up of 60 months, cohort-1 had longer survival free of hospital readmissions for HF (37.5% vs. 92%; p < 0.001) and cardiovascular mortality (26.2% vs. 71.9%; p < 0.001), with differences from the first month. CONCLUSIONS: Patients with HFrEF and ≥2 previous admissions for HF have a higher proportion of comorbidities. These patients are associated with worse reverse remodelling and worse medium- and long-term prognoses from the early stages, wherein early identification is essential for close follow-up and optimal intensive treatment.

Improvement of left ventricular ejection fraction in patients with heart failure with reduced ejection fraction: Predictors and clinical impact / Impacto clínico a medio plazo de la mejoría de la fracción de eyección ventricular izquierda en pacientes con insuficiencia cardiaca con fracción de eyección reducida

Background A percentage of patients with heart failure with reduced ejection fraction (HFrEF) improve left ventricular ejection fraction (LVEF) in the evolution. This entity, defined for the first time in an international consensus as heart failure with improved ejection fraction (HFimpEF), could have a different clinical profile and prognosis than HFrEF. Our main aim was to analyze the differential clinical profile between the two entities, as well as the mid-term prognosis. Material-methods Prospective study of a cohort of patients with HFrEF who had echocardiographic data at baseline and follow-up. A comparative analysis of patients who improved LVEF with those who did not was made. Clinical, echocardiographic and therapeutic variables were analyzed, and the mid-term impact in terms of mortality and hospital readmissions for HF was assessed. Results Ninety patients were analyzed. Mean age was 66.5(10.4) years, with a male predominance (72.2%). Forty five patients (50%) improved LVEF (Group-1,HFimpEF) and forty five patients (50%) sustained reduced LVEF (Group-2,HFsrEF). The mean time to LVEF improvement in Group-1 was 12.6(5.7) months. Group-1 had a more favorable clinical profile: lower prevalence of cardiovascular risk factors, higher prevalence of de novo HF (75.6% vs. 42.2%; p<0.05), lower prevalence of ischemic etiology (22.2% vs. 42.2%; p<0.05), with less basal dilatation of the left ventricle. At the end of follow-up (mean 19(1) months) Group-1 had a lower hospital readmission rate (3.1% vs. 26.7%; p<0.01), as well as lower mortality (0% vs. 24.4%; p<0.01). Conclusion Patients with HFimpEF seem to have a better mid-term prognosis in terms of reduced mortality and hospital admissions. This improvement could be conditioned by the clinical profile of patients HFimpEF (AU)

Introducción Un porcentaje de pacientes con insuficiencia cardiaca y fracción de eyección reducida (IC-FEr) mejoran la fracción de eyección ventricular izquierda (FEVI) en la evolución. Esta entidad se ha definido por primera vez en un consenso internacional como insuficiencia cardiaca y fracción de eyección mejorada (IC-FEm), y podría tener un perfil y pronóstico diferente que IC-FEr. Nuestro objetivo fue analizar el perfil de ambas entidades y su pronóstico a medio plazo. Material y métodos Estudio prospective de una cohorte de pacientes con IC-FEr que tenían datos ecocardiográficos basales y en el seguimiento. Se hizo un análisis comparativo de pacientes con IC-FEm y pacientes con insuficiencia cardiaca y IC-FEpr. Se analizaron variables clínicas, ecocardiográficas y de tratamiento; el impacto clínico a medio plazo se analizó en términos de mortalidad y reingresos hospitalarios por insuficiencia cardiaca. Resultados Se analizaron 90 pacientes, edad media 66,5 (10,4) años (72,2% mujeres). La mitad de los pacientes mejoraron su FEVI, con un tiempo medio hasta la mejoría de 12,6 (5,7) meses. El grupo IC-FEm tenía un perfil clínico más favorable: menor proporción de factores de riesgo cardiovascular, prevalencia más elevada de IC-novo (75,6 vs. 42,2%; p < 0,05), y menor proporción de isquemia (22,2 vs. 42.2%; p < 0,05). Los pacientes con IC-FEm en el seguimiento a medio plazo tenían menor tasa de reingresos (3,1 vs. 26,7%; p < 0,01), y mortalidad (0 vs. 24,4%; p < 0,01). Conclusión Pacientes con IC-FEm parecen tener un mejor pronóstico en términos de mortalidad y reingresos hospitalarios por insuficiencia cardiaca (IC). Esta mejoría clínica podría estar condicionada por el perfil de los pacientes con IC-FEm (AU)

Improvement of left ventricular ejection fraction in patients with heart failure with reduced ejection fraction: Predictors and clinical impact.

BACKGROUND: A percentage of patients with heart failure with reduced ejection fraction (HFrEF) improve left ventricular ejection fraction (LVEF) in the evolution. This entity, defined for the first time in an international consensus as heart failure with improved ejection fraction (HFimpEF), could have a different clinical profile and prognosis than HFrEF. Our main aim was to analyze the differential clinical profile between the two entities, as well as the mid-term prognosis. MATERIAL-METHODS: Prospective study of a cohort of patients with HFrEF who had echocardiographic data at baseline and follow-up. A comparative analysis of patients who improved LVEF with those who did not was made. Clinical, echocardiographic and therapeutic variables were analyzed, and the mid-term impact in terms of mortality and hospital readmissions for HF was assessed. RESULTS: Ninety patients were analyzed. Mean age was 66.5(10.4) years, with a male predominance (72.2%). Forty five patients (50%) improved LVEF (Group-1,HFimpEF) and forty five patients (50%) sustained reduced LVEF (Group-2,HFsrEF). The mean time to LVEF improvement in Group-1 was 12.6(5.7) months. Group-1 had a more favorable clinical profile: lower prevalence of cardiovascular risk factors, higher prevalence of de novo HF (75.6% vs. 42.2%; p<0.05), lower prevalence of ischemic etiology (22.2% vs. 42.2%; p<0.05), with less basal dilatation of the left ventricle. At the end of follow-up (mean 19(1) months) Group-1 had a lower hospital readmission rate (3.1% vs. 26.7%; p<0.01), as well as lower mortality (0% vs. 24.4%; p<0.01). CONCLUSION: Patients with HFimpEF seem to have a better mid-term prognosis in terms of reduced mortality and hospital admissions. This improvement could be conditioned by the clinical profile of patients HFimpEF.

Risk scores for predicting incident heart failure admission in patients with chronic coronary syndromes: Validation in a prospective, monocentric, long-term, cohort study.

BACKGROUND: Heart failure (HF) admission in chronic coronary syndrome (CCS) patients has a prognostic impact. Stratification schemes have been described for predicting this endpoint, but none of them has been externally validated. OBJECTIVES: Our aim was to develop point scores for predicting incident HF admission with data from previous studies, to perform an external validation in an independent prospective cohort and to compare their discriminative ability for this event. METHODS: Independent predictive variables of HF admission in CCS patients without baseline HF were selected from four previous prospective studies (CARE, PEACE, CORONOR and CLARIFY), generating scores based on the relative magnitude of the coefficients of Cox of each variable. Finally, the scores were validated and compared in a monocentric prospective cohort. RESULTS: The validation cohort included 1212 patients followed for up to 17 years, with 171 patients suffering at least one HF admission in the follow-up. Discriminative ability for predicting HF admission was statistically significant for all, and paired comparisons among them were all nonsignificant except for CORONOR score was superior to CLARIFY score (C-statistic 0.73, 95%CI 0.69-0.76 vs. 0.69, 95% CI 0.65-0.73; p = 0.03). CONCLUSION: All tested scores showed significant discriminative ability for predicting incident HF admission in this independent validation study. Their discriminative ability was similar, with significant differences only between the two scores with higher and lower performance.

Alteraciones electrocardiográficas y necesidad de marcapasos en amiloidosis cardiaca: análisis de 58 casos / Electrocardiographic features and need for pacemaker in cardiac amyloidosis: Analysis of 58 cases

ObjetivoEn la amiloidosis cardiaca (AC) el material amiloide puede depositarse en diferentes estructuras cardiacas pudiendo producir diferentes alteraciones electrocardiográficas. El objetivo fue describir qué alteraciones electrocardiográficas son más frecuentes en pacientes con AC, analizando su impacto en la necesidad de marcapasos.MetodosEstudio retrospectivo que incluye pacientes diagnosticados de AC por cadenas ligeras (AC-AL) y AC por transtirretina (AC-TTR), entre enero-2013 y marzo-2021. Se analizó el ritmo basal, el porcentaje con patrón de seudoinfarto, bajo voltaje o alteraciones de la conducción; también se analizó el impacto en la necesidad de marcapasos definitivo.ResultadosSe incluyeron 58 pacientes con AC (20 AC-AL, 38 AC-TTR). Varones (69%), 21 (36%) tenían FA al diagnóstico. El 60% tenía patrón de seudoinfarto, el 35% bajo voltaje y un 22% tenían criterios de hipertrofia ventricular. Dos tercios tenían algún trastorno de conducción: bloqueo auriculoventricular de primer grado, 18 pacientes (31%); 12 bloqueo completo de rama derecha (BCRD), 3 bloqueo completo de rama izquierda (BCRI) y 25 con un hemibloqueo de rama. No hubo diferencias entre AC-AL y AC-TTR. Los pacientes con AC-TTR tuvieron mayor necesidad de marcapasos en el seguimiento (39±40 meses). El bloqueo completo de rama (BCR) fue un predictor de necesidad de marcapasos permanente (HR: 23,43; IC 95%: 4,09-134,09; p=0,01).ConclusionesLas alteraciones electrocardiográficas en pacientes diagnosticados de AC son heterogéneas, siendo la más frecuente la presencia de trastornos de conducción, el patrón de seudoinfarto, seguido del de bajo voltaje. Los pacientes con cualquier BCR en el electrocardiograma basal son más propensos a precisar marcapasos en el seguimiento, sobre todo en AC-TTR. (AU)

AimAmyloidosis is a disease in which amyloid fibrils can be deposited in different cardiac structures, and several electrocardiographic abnormalities can be produced by this phenomenon. The objective of this study was to describe the most common basal electrocardiographic alterations in patients diagnosed with cardiac amyloidosis (CA) and to determine if these abnormalities have an impact on the need of pacemaker.MethodsThis retrospective study included patients who had an established diagnosis of CA [light-chain cardiac amyloidosis (LA-CA) or transthyretin cardiac amyloidosis (TTR-CA)] between January 2013 and March 2021. The baseline heart rate, the percentage of patients with a pseudo-infarct pattern, low-voltage pattern or cardiac conductions disturbances, and the impact of these factors on the need of pacemaker were analysed.ResultsFifty-eight patients with CA (20 with LA-CA and 38 with TTR-CA) were included, and the majority were male (69.0%). Twenty-one patients had atrial fibrillation (AF) at diagnosis. Thirty-five patients had a pseudo-infarct pattern, 35% had a low-voltage pattern, and 22% had criteria for ventricular hypertrophy. Two hirds had a conduction disorder: 18 patients with first degree atrioventricular block, 12 right bundle branch block, 3 left bundle branch block and 25 with a branch hemiblock. There were no differences between LA-CA and TTR-CA. Patients with TTR-CA had a greater need for pacemakers in the folow-up (39±40 meses). Bundle branch block was a predictor of the need for a permanent pacemaker (HR: 23.43; CI 95%: 4.09.134.09; P=.01).ConclusionsElectrocardiographic abnormalities in patients diagnosed wich CA are heterogeneus. Most frecuent is the presence of conduction disorders, the pseudoinfarction pattern, followed by the low voltage pattern. Patients with any bundle branch block at the baseline electrocardiogram need more frecuent to require a pacemaker during follow-up, especially in TTR-CA. (AU)

Electrocardiographic features and need for pacemaker in cardiac amyloidosis: Analysis of 58 cases. / Alteraciones electrocardiográficas y necesidad de marcapasos en amiloidosis cardiaca: análisis de 58 casos.

AIM: Amyloidosis is a disease in which amyloid fibrils can be deposited in different cardiac structures, and several electrocardiographic abnormalities can be produced by this phenomenon. The objective of this study was to describe the most common basal electrocardiographic alterations in patients diagnosed with cardiac amyloidosis (CA) and to determine if these abnormalities have an impact on the need of pacemaker. METHODS: This retrospective study included patients who had an established diagnosis of CA [light-chain cardiac amyloidosis (LA-CA) or transthyretin cardiac amyloidosis (TTR-CA)] between January 2013 and March 2021. The baseline heart rate, the percentage of patients with a pseudo-infarct pattern, low-voltage pattern or cardiac conductions disturbances, and the impact of these factors on the need of pacemaker were analysed. RESULTS: Fifty-eight patients with CA (20 with LA-CA and 38 with TTR-CA) were included, and the majority were male (69.0%). Twenty-one patients had atrial fibrillation (AF) at diagnosis. Thirty-five patients had a pseudo-infarct pattern, 35% had a low-voltage pattern, and 22% had criteria for ventricular hypertrophy. Two hirds had a conduction disorder: 18 patients with first degree atrioventricular block, 12 right bundle branch block, 3 left bundle branch block and 25 with a branch hemiblock. There were no differences between LA-CA and TTR-CA. Patients with TTR-CA had a greater need for pacemakers in the folow-up (39±40 meses). Bundle branch block was a predictor of the need for a permanent pacemaker (HR: 23.43; CI 95%: 4.09.134.09; P=.01). CONCLUSIONS: Electrocardiographic abnormalities in patients diagnosed wich CA are heterogeneus. Most frecuent is the presence of conduction disorders, the pseudoinfarction pattern, followed by the low voltage pattern. Patients with any bundle branch block at the baseline electrocardiogram need more frecuent to require a pacemaker during follow-up, especially in TTR-CA.

Impact of frailty and atrial fibrillation in elderly patients with acute coronary syndromes.

BACKGROUND: There is scarce information on the prognostic role of frailty and atrial fibrillation (AF) in elderly patients with acute coronary syndrome (ACS). METHODS: The aim was to analyse the management of elderly patients with frailty and AF who suffered an ACS using data of the prospective multicentre LONGEVO-SCA registry. We evaluated the predictive performance of FRAIL, Charlson scores and AF status for adverse events at 6-month follow-up. RESULTS: A total of 531 unselected patients with ACS and above 80 years old [mean age 84.4 (SD = 3.6) years; 322 (60.6%) male] were enrolled, of whom 128 (24.1%) with AF and 145 (27.3%) with frailty. Mutually exclusive number of patients were as follows: non-frail and sinus rhythm (SR) 304 (57.2%); frail and SR 99 (18.6%); non-frail and AF 82 (15.4%); and frail and AF 46 (8.7%). Frail and AF patients compared with non-frail and SR patients had higher risk of all-cause mortality [HR 2.61, (95% CI 1.28-5.31; P = .008)], readmissions [HR 2.28, (95%CI 1.37-3.80); P = .002)] and its composite [HR 2.28, (95% CI 1.44-3.60); P < .001)]. After multivariate adjustment, FRAIL score [HR 1.41, (95% CI 1.02-1.97); P = .040] and Charlson index [HR 1.32, (95% CI 1.09-1.59); P = .003] were significantly associated with mortality. AF status was not independently related with adverse events. CONCLUSIONS: Frailty but not AF status was independently associated with follow-up adverse events. Frailty status and high Charlson index were independent conditions associated with adverse events during the follow-up. The impact of functional status has a bigger prognostic role over AF status in elderly patients with ACS.

Consenso de expertos en la asistencia multidisciplinaria y el abordaje integral de la insuficiencia cardiaca. Desde el alta hospitalaria hasta la continuidad asistencial con primaria / Expert consensus on multidisciplinary management and integrated approaches in heart failure. Continuity of care from hospital discharge to primary care

La insuficiencia cardiaca es una enfermedad que precisa un tratamiento multidisciplinario, dadas la diversidad de causas y entornos clínicos implicados que las tratan y las diferentes estrategias terapéuticas que precisan la participación indispensable de diversas disciplinas. La presencia en los servicios de cardiología de unidades de insuficiencia cardiaca centradas en el tratamiento de los pacientes con esta afección y unidades de rehabilitación cardiaca que, entre sus indicaciones para la reducción de la morbimortalidad, también están implicadas en la atención de esos mismos pacientes puede causar dificultades de coordinación y pérdida de una atención integral centrada en el paciente. Por estos motivos, en el presente documento se plantea una estrategia de coordinación entre las diferentes unidades implicadas en el tratamiento de los pacientes dentro de los servicios de cardiología y la continuidad asistencial con atención primaria, tanto tras haber conseguido la estabilidad como la interrelación para una coordinación posterior más efectiva

Heart failure is a condition that requires a multidisciplinary approach to treatment because of the wide range of causes and clinical contexts that may be involved and because the diverse treatment strategies used necessitate the participation of multiple disciplines. In cardiology departments, the presence of both heart failure units that focus on the treatment of affected patients and cardiac rehabilitation units that, as well as targeting reductions in morbidity and mortality, are also involved in caring for the same patients can create difficulties for coordination and can result in the loss of comprehensive patient-centered care. For these reasons, this paper presents a strategy for coordinating the different units involved in patient management in cardiology departments and for ensuring continuity of care in primary care, both immediately after achieving stabilization and subsequently, when these interactions are important for effective coordination

Supervivencia a largo plazo de una población española con cardiopatía isquémica estable: el registro CICCOR / Long-term survival in a Spanish population with stable ischemic heart disease. The CICCOR registry

Introducción y objetivos: La información sobre el pronóstico de la cardiopatía isquémica crónica (CIC) es escasa. El objetivo es analizar los predictores de la mortalidad y la supervivencia a largo plazo de estos pacientes. Métodos: Estudio de cohortes prospectivo y monocéntrico que reclutó a 1.268 pacientes con CIC desde enero de 2000 hasta febrero de 2004. Se registraron los fallecimientos durante el seguimiento. Se compararon las tasas de mortalidad total y cardiovascular ajustadas con la población española. Se investigó la asociación de variables basales con la mortalidad. Resultados: La media de edad fue 68+/-10 años; el 73% eran varones. Tras 17 años de seguimiento máximo (mediana, 11 años), murieron 629 pacientes (50%). La edad (HR=1,08; IC95%, 1,07-1,11; p<0,001), la diabetes (HR=1,36; IC95%, 1,14-1,63; p <0,001), la frecuencia cardiaca (HR=1,01; IC95%, 1,00-1,02; p <0,001), la fibrilación auricular (HR=1,61; IC95%, 1,22-2,14); p=0,001), las alteraciones electrocardiográficas (HR=1,23; IC95%, 1,02-1,49; p=0,02) y el tabaquismo (HR=1,85; IC95%, 1,31-2,80; p=0,001) han resultado predictores independientes de la mortalidad total. La tasa de mortalidad total fue mayor que en la población española (47,81 frente a 36,29/1.000 pacientes/año; razón de mortalidad estandarizada=1,31; IC95%, 1,21-1,41). La tasa de mortalidad cardiovascular fue 15,25 frente a 6,94/1.000 pacientes/año de la población general (razón de mortalidad estandarizada=2,19; IC95%, 1,88-2,50). Conclusiones: En esta muestra de pacientes con CIC, la tasa de mortalidad fue significativamente mayor que en la población general. Las variables clínicas identifican a los pacientes con mayor riesgo de muerte en el seguimiento

Introduction and objectives: Data are lacking on the long-term prognosis of stable ischemic heart disease (SIHD). Our aim was to analyze long-term survival in patients with SIHD and to identify predictors of mortality. Methods: A total of 1268 outpatients with SIHD were recruited in this single-center prospective cohort study from January 2000 to February 2004. Cardiovascular and all-cause death during follow-up were registered. All-cause and cardiovascular mortality rates were compared with those in the Spanish population adjusted by age, sex, and year. Predictors of these events were investigated. Results: The mean age was 68+/-10 years and 73% of the patients were male. After a follow-up lasting up to 17 years (median 11 years), 629 (50%) patients died. Independent predictors of all-cause mortality were age (HR, 1.08; 95%CI, 1.07-1.11; P <.001), diabetes (HR, 1.36; 95%CI, 1.14-1.63; P <.001), resting heart rate (HR, 1.01; 95%CI, 1.00-1.02; P <.001), atrial fibrillation (HR, 1.61; 95%CI, 1.22-2.14; P=.001), electrocardiographic changes (HR, 1.23; 95%CI, 1.02-1.49; P=.02) and active smoking (HR, 1.85; 95%CI, 1.31-2.80; P=.001). All-cause mortality and cardiovascular mortality rates were significantly higher in the sample than in the general Spanish population (47.81/1000 patients/y vs 36.29/1000 patients/y (standardized mortality rate, 1.31; 95%CI, 1.21-1.41) and 15.25/1000 patients/y vs 6.94/1000 patients/y (standardized mortality rate, 2.19; 95%CI, 1.88-2.50, respectively). Conclusions: The mortality rate was higher in this sample of patients with SIHD than in the general population. Several clinical variables can identify patients at higher risk of death during follow-up

Long-term Survival in a Spanish Population With Stable Ischemic Heart Disease. The CICCOR Registry.

INTRODUCTION AND OBJECTIVES: Data are lacking on the long-term prognosis of stable ischemic heart disease (SIHD). Our aim was to analyze long-term survival in patients with SIHD and to identify predictors of mortality. METHODS: A total of 1268 outpatients with SIHD were recruited in this single-center prospective cohort study from January 2000 to February 2004. Cardiovascular and all-cause death during follow-up were registered. All-cause and cardiovascular mortality rates were compared with those in the Spanish population adjusted by age, sex, and year. Predictors of these events were investigated. RESULTS: The mean age was 68±10 years and 73% of the patients were male. After a follow-up lasting up to 17 years (median 11 years), 629 (50%) patients died. Independent predictors of all-cause mortality were age (HR, 1.08; 95%CI, 1.07-1.11; P <.001), diabetes (HR, 1.36; 95%CI, 1.14-1.63; P <.001), resting heart rate (HR, 1.01; 95%CI, 1.00-1.02; P <.001), atrial fibrillation (HR, 1.61; 95%CI, 1.22-2.14; P=.001), electrocardiographic changes (HR, 1.23; 95%CI, 1.02-1.49; P=.02) and active smoking (HR, 1.85; 95%CI, 1.31-2.80; P=.001). All-cause mortality and cardiovascular mortality rates were significantly higher in the sample than in the general Spanish population (47.81/1000 patients/y vs 36.29/1000 patients/y (standardized mortality rate, 1.31; 95%CI, 1.21-1.41) and 15.25/1000 patients/y vs 6.94/1000 patients/y (standardized mortality rate, 2.19; 95%CI, 1.88-2.50, respectively). CONCLUSIONS: The mortality rate was higher in this sample of patients with SIHD than in the general population. Several clinical variables can identify patients at higher risk of death during follow-up.

Endocarditis infecciosa sobre válvula nativa del lado izquierdo: influencia de la edad y de cardiopatía previa / Left-sided native valve infective endocarditis: Influence of age and the presence of underlying heart disease

Introducción y objetivos: La epidemiología de la endocarditis infecciosa sobre válvula nativa izquierda (EIVNI) se ha modificado, consecuencia del aumento en la edad media de los pacientes. El objetivo de nuestro estudio es analizar la influencia de la edad y la presencia de una cardiopatía predisponente previa en el pronóstico de estos pacientes. Métodos: Analizamos 257 casos consecutivos de EIVNI en función de su edad, tanto en la serie global como en el subgrupo de pacientes sin cardiopatía predisponente. Resultados: La edad media fue de 54,6 (18,6) años. Existió un aumento en la proporción de pacientes de edad igual o mayor a 70 años entre 1987-2000 y 2001-2014 (9,8 frente a 34,8%, p < 0,001), que presentaban una mayor prevalencia de valvulopatía degenerativa (50 frente a 22,8%), ausencia de cardiopatía (50 frente a 39,9%), p < 0,001, casos relacionados con atención sanitaria (41,8 frente a 23,6%, p = 0,016), menor tasa de cirugía (43,7 frente a 63,8%, p = 0,005) y mayor mortalidad hospitalaria (39,1 frente a 20,7%, p = 0,003), sin diferencias respecto a comorbilidades. Los pacientes sin cardiopatía también presentaron una mortalidad hospitalaria más elevada (47 frente a 22%, p = 0,01). La edad igual o mayor a 70 años constituye un predictor independiente de mortalidad en pacientes con EIVNI (OR 2,53, IC 95% 1,24-5,15, p = 0,011), igual que en aquellos que no presentan cardiopatía (OR 3,98, IC 95% 1,49-10,62, p = 0,006). Conclusiones: Los pacientes que tienen una edad igual o mayor a 70 años con un episodio de EIVNI son cada vez más frecuentes y presentan peor pronóstico, con una tasa menor de cirugía y mayores tasas de mortalidad hospitalaria (AU)

Introduction and objectives: Left-sided native valve infective endocarditis (LNVIE) epidemiology has been modified as a result of the increase in average age. The aim of our study is to analyze the influence of age and the presence of predisposing heart disease in the prognosis of these patients. Methods: We analyzed a series of 257 cases of LNVIE depending on their age (greater than or equal to 70 years old), both in the overall series and in the subgroup of patients without predisposing heart disease. Results: Mean age was 54.6 (18.6) years. There was an increase in the percentage of cases of older patients between 1987-2000 and 2001-2014 (9.8 vs. 34.8%, P < .001). These patients present higher prevalence of degenerative valves (50 vs. 22.8%) or not predisposing heart disease (50 vs. 39.9%), P < .001, health-care associated episodes (41.8 vs. 23.6%, P = .016), lower rate of surgery (43.7 vs. 63.8%, P = .005) and higher in-hospital mortality (39.1 vs. 20.7%, P = .003), with no differences in comorbidities. Older patients who did not have predisposing heart disease also suffered higher in-hospital mortality (47 vs. 22%, P = .01).Age greater than or equal to 70 years old is an independent predictor of mortality in patients with LNVIE (OR 2.53, 95% CI 1.24-5.15, P = .011), as in those without previous heart disease (OR 3.98, 95% CI 1.49-10.62, P = .006). Conclusions: Patients of age greater than or equal to 70 years old and who suffer an LNVIE are becoming more frequent and have a worse prognosis with a lower rate of surgery and higher rates of in-hospital mortality (AU)

[Left-sided native valve infective endocarditis: Influence of age and the presence of underlying heart disease]. / Endocarditis infecciosa sobre válvula nativa del lado izquierdo: influencia de la edad y de cardiopatía previa.

INTRODUCTION AND OBJECTIVES: Left-sided native valve infective endocarditis (LNVIE) epidemiology has been modified as a result of the increase in average age. The aim of our study is to analyze the influence of age and the presence of predisposing heart disease in the prognosis of these patients. METHODS: We analyzed a series of 257 cases of LNVIE depending on their age (greater than or equal to 70 years old), both in the overall series and in the subgroup of patients without predisposing heart disease. RESULTS: Mean age was 54.6 (18.6) years. There was an increase in the percentage of cases of older patients between 1987-2000 and 2001-2014 (9.8 vs. 34.8%, P<.001). These patients present higher prevalence of degenerative valves (50 vs. 22.8%) or not predisposing heart disease (50 vs. 39.9%), P<.001, health-care associated episodes (41.8 vs. 23.6%, P=.016), lower rate of surgery (43.7 vs. 63.8%, P=.005) and higher in-hospital mortality (39.1 vs. 20.7%, P=.003), with no differences in comorbidities. Older patients who did not have predisposing heart disease also suffered higher in-hospital mortality (47 vs. 22%, P=.01). Age greater than or equal to 70 years old is an independent predictor of mortality in patients with LNVIE (OR 2.53, 95% CI 1.24-5.15, P=.011), as in those without previous heart disease (OR 3.98, 95% CI 1.49-10.62, P=.006). CONCLUSIONS: Patients of age greater than or equal to 70 years old and who suffer an LNVIE are becoming more frequent and have a worse prognosis with a lower rate of surgery and higher rates of in-hospital mortality.

Efectos sobre la mortalidad y reingresos hospitalarios de tres tipos distintos de programas de intervención en pacientes hospitalizados por insuficiencia cardiaca: ensayo clínico aleatorizado / Effects of three different disease management programs on outcomes in patients hospitalized with heart failure: a randomized trial

Fundamento y objetivo: A pesar del reconocido beneficio de los programas de intervención en pacientes con insufiencia cardiaca (IC), se desconoce si los diferentes tipos de programas tienen una eficacia similar. El objetivo de nuestro estudio fue comparar la efectividad de tres tipos diferentes de intervención. Pacientes y método:Se aleatorizaron 208 pacientes dados de alta consecutivamente después de un ingreso por IC desde enero de 2007: 52 fueron aleatorizados a cada grupo de intervención (seguimiento intensivo hospitalario y una visita domiciliaria o llamada telefónica a los 15 días del alta) y otros 52 a seguimiento habitual. Resultados: El seguimiento medio (DE) fue de 10,8 (3,9) meses. Durante el estudio alcanzaron el objetivo primario (muerte u hospitalización por IC): 20 pacientes (38,5%) en el grupo control, 19 (36,5%) en el de seguimiento telefónico (hazard ratio [HR] 1,11; intervalo de confianza del 95% [IC 95%] 0,59-2,01, p=0,79), 24 (46,2%) en el de domicilio (HR 1,27; IC 95% 0,69-2,32, p=0,78) y 23 pacientes (44,2%) en el de seguimiento intensivo (HR 1,33; IC 95% 0,73-0,42, p=0,79). Se observó una tendencia a un mayor número de ingresos hospitalarios (aunque de duración más corta) por IC en el grupo de seguimiento intensivo, con una tendencia a una menor mortalidad en los grupos de intervención: 23,1% frente al 33,3% del grupo control (HR 0,61 IC 95% 0,35-1,01, p=0,08). Conclusión: En nuestro estudio no hemos encontrado diferencias entre tres tipos diferentes de programas de intervención, sin observar un beneficio significativo sobre el pronóstico en relación con el grupo control, constatando un ligero incremento de estancias hospitalarias cortas en el grupo de seguimiento intensivo (AU)

Background and objectiveDespite the recognized benefit of intervention programs in patients with heart failure (HF), it is unknown whether different types of programs have similar efficacy. The aim of our study was to compare the effectiveness of three different types of intervention.Patients and methods208 patients discharged with the diagnosis of HF were randomized. Fifty-two were assigned to each one of different groups of intervention (home visits, telephone follow-up, HF unit) and 52 patients to usual care (control group). Results: Median follow-up was 10.8±3.2 months. During the study, the primary end point (HF hospitalization or death) was reached in: 20 patients (38.5%) in control group, 19 (36.5%) in telephone follow-up (HR 1.11; IC95% [0.59-2.01], p=0.79), 24 (46.2%) in home visits (HR 1.27; IC95% [0.69-2.32], p=0.78) and 23 patients (44.2%) in HF unit (HR 1.33; IC95% [0.73-0.42], p=0.79). There was a trend to higher hospitalizations (shorter) with lower mortality in intervention groups (mortality: 23.1% intervention groups vs 33.3% in control group, HR 0.61 IC al 95% [0.35-1.01], p=0.08). Conclusions: In our study, the application of three different intervention programs in patients with HF has a little non-significant prognosis benefit, with a slight increase in the number of shorts hospitalizations in HF unit (AU)

[Effects of three different disease management programs on outcomes in patients hospitalized with heart failure: a randomized trial]. / Efectos sobre la mortalidad y reingresos hospitalarios de tres tipos distintos de programas de intervención en pacientes hospitalizados por insuficiencia cardiaca: ensayo clínico aleatorizado.

BACKGROUND AND OBJECTIVE: Despite the recognized benefit of intervention programs in patients with heart failure (HF), it is unknown whether different types of programs have similar efficacy. The aim of our study was to compare the effectiveness of three different types of intervention. PATIENTS AND METHODS: 208 patients discharged with the diagnosis of HF were randomized. Fifty-two were assigned to each one of different groups of intervention (home visits, telephone follow-up, HF unit) and 52 patients to usual care (control group). RESULTS: Median follow-up was 10.8±3.2 months. During the study, the primary end point (HF hospitalization or death) was reached in: 20 patients (38.5%) in control group, 19 (36.5%) in telephone follow-up (HR 1.11; IC95% [0.59-2.01], p=0.79), 24 (46.2%) in home visits (HR 1.27; IC95% [0.69-2.32], p=0.78) and 23 patients (44.2%) in HF unit (HR 1.33; IC95% [0.73-0.42], p=0.79). There was a trend to higher hospitalizations (shorter) with lower mortality in intervention groups (mortality: 23.1% intervention groups vs 33.3% in control group, HR 0.61 IC al 95% [0.35-1.01], p=0.08). CONCLUSIONS: In our study, the application of three different intervention programs in patients with HF has a little non-significant prognosis benefit, with a slight increase in the number of shorts hospitalizations in HF unit.

Estudio SHIFT: papel de la ivabradina en la insuficiencia cardiaca y su importancia en la práctica clínica / The SHIFT study: the role of ivabradine in the treatment of heart failure and its relevance in clinical practice

El Systolic Heart failure treatment with If inhibitor ivabradine Trial (SHIFT) es un estudio de referencia sobre un enfoque novedoso en el tratamiento de los pacientes con insuficiencia cardiaca, acorde con el hecho de que la frecuencia cardiaca elevada no sólo es un marcador de riesgo, sino también un factor de riesgo modificable con potencial para ser objetivo terapéutico en pacientes con insuficiencia cardiaca y función sistólica deprimida. Incluyó a 6.558 pacientes con insuficiencia cardiaca crónica, disfunción sistólica ventricular izquierda (fracción de eyección ≤ 35%) y ritmo sinusal ≥ 70lpm; se objetivó con ivabradina un beneficio adicional en la reducción del combinado de muerte cardiovascular o reingreso por insuficiencia cardiaca, a expensas fundamentalmente de la reducción de las hospitalizaciones por reagudización de la clínica congestiva. Asimismo, tenía un efecto adicional en el proceso de remodelado ventricular y en la calidad de vida, con una tasa muy baja de efectos secundarios. La combinación de la eficacia y la seguridad de este fármaco es un hecho que sin duda determina la inclusión de la ivabradina en las guías de práctica clínica de insuficiencia cardiaca (AU)

The Systolic Heart failure treatment with I f inhibitor ivabradine Trial (SHIFT) is a case-referent study of a novel approach to the treatment of patients with heart failure. The rationale is that a high heart rate is not only a risk marker for disease but is also a modifiable risk factor that could serve as a therapeutic target in patients with heart failure and depressed systolic function. The study enrolled 6558 patients with chronic heart failure, left ventricular systolic dysfunction (i.e. an ejection fraction ≤35%) and a sinus rhythm of 70 beats/min or higher. It was found that the addition of ivabradine resulted in a reduction in the combined endpoint of cardiovascular death or readmission for heart failure, which was mainly due to a reduction in hospitalization for exacerbations of congestive symptoms. In addition, ivabradine also had an additive effect on ventricular remodeling and quality of life, and the adverse effect rate was very low. Taken together, the favorable efficacy and safety of this drug guarantee ivabradine’s inclusion in clinical practice guidelines for heart failure (AU)

Pronóstico a corto y largo plazo de la endocarditis sobre prótesis en pacientes no drogadictos / Short and long-Term prognosis of prosthetic valve endocarditis in non-addicts

Introducción y objetivos. La endocarditis infecciosa sobre prótesis es una enfermedad con una elevada morbimortalidad durante la fase activa y un riesgo importante de complicaciones en el seguimiento. El objetivo de nuestro estudio es conocer las características clínicas, así como la evolución a corto y largo plazo de estos enfermos. Pacientes y métodos. Estudio prospectivo de 43 casos consecutivos de endocarditis sobre prótesis en pacientes no drogadictos entre enero de 1987 y marzo de 1997.Resultados. La edad media de los pacientes era de 51 ñ 16 años. Hubo 8 casos (19 por ciento) de endocarditis sobre prótesis precoz (en los dos meses siguientes a la cirugía cardíaca), 14 (32 por ciento) de endocarditis sobre prótesis intermedia (entre los dos y doce meses poscirugía) y 21 (49 por ciento) de endocarditis sobre prótesis tardía (más allá del primer año de la cirugía). Se realizó un ecocardiograma transesofágico a 32 pacientes, con una sensibilidad del 81 por ciento. Presentaron algún tipo de complicación el 86 por ciento de los casos y fueron intervenidos en la fase activa de la enfermedad el 53 por ciento de los casos (25 por ciento con carácter urgente). La mortalidad hospitalaria fue del 23 por ciento (el 50 por ciento para la endocarditis sobre prótesis precoz). Tras un seguimiento medio de 56 meses, hubo 5 casos de recurrencia, necesitaron cirugía cuatro pacientes y fallecieron cinco.La supervivencia, excluyendo la mortalidad precoz, fue del 82 por ciento a los 5 años, no existiendo diferencias significativas entre los pacientes que recibieron tratamiento médico solo y los que fueron intervenidos en la fase activa. Conclusiones. La mortalidad precoz de la endocarditis sobre prótesis, según la experiencia de nuestro centro, está en torno al 20 por ciento. El pronóstico de los supervivientes a la fase activa de la enfermedad es favorable en la mayoría de los casos. La endocarditis sobre prótesis precoz continúa teniendo una elevada mortalidad temprana a pesar de utilizar un tratamiento combinado medicoquirúrgico (AU)

Endocarditis por fiebre Q. Evolución tórpida a largo plazo / Q fever endocarditis. Torpid long-term outcome

No disponible

Características generales y resultados a corto y largo plazo de la endocarditis infecciosa en pacientes no drogadictos / General Features and Short and Long-Term Results of Infective Endocarditis in Non-Drug Addicts

Introducción y objetivos. La endocarditis infecciosa es una enfermedad con una morbimortalidad elevada en la fase activa y con un riesgo no despreciable de complicaciones en el seguimiento. El objetivo de este estudio es conocer las características clínicas y pronósticas de la endocarditis infecciosa a corto y a largo plazo en pacientes no drogadictos. Pacientes y métodos. Un estudio prospectivo de 138 casos de endocarditis infecciosa en pacientes no adictos a drogas por vía parenteral tratados en nuestro centro desde 1987 hasta 1997. Resultados. La edad media de los pacientes fue 44 ñ 20 años. Noventa y cinco casos (69 por ciento) fueron endocarditis sobre válvula nativa y cuarenta y tres (31 por ciento) endocarditis sobre prótesis. Los estreptococos causaron el 34 por ciento de los casos y los estafilococos el 33 por ciento. El 83 por ciento de los pacientes desarrolló algún tipo de complicación en la fase hospitalaria. Fueron intervenidos en la fase activa de la enfermedad el 51 por ciento de los pacientes, siendo en el 22 por ciento de los casos con carácter urgente. La mortalidad hospitalaria fue del 21 por ciento. En el seguimiento fueron intervenidos diez pacientes (9 por ciento) y fallecieron siete (5 por ciento del total de la serie). La supervivencia global a los 10 años es del 71 por ciento. No hubo diferencias estadísticas en la supervivencia en cuanto al tipo de tratamiento (médico o quirúrgico) recibido en la fase activa. Conclusiones. Una tasa elevada de cirugía en la fase activa se asocia con una supervivencia favorable a largo plazo sin aumentar la mortalidad precoz. El tratamiento médico ofrece también unos resultados favorables a largo plazo en los casos de endocarditis infecciosa sin factores de mal pronóstico y buena evolución (AU)